Press Releases

LONDON --(BUSINESS WIRE)--Sep. 21, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023 . Dolci will continue in his role and support the

LONDON --(BUSINESS WIRE)--Sep. 20, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m.   London time ( 8 a.m. Eastern Time ).

LONDON --(BUSINESS WIRE)--Aug. 30, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM) , which provides accurate and continuous

LONDON --(BUSINESS WIRE)--Aug. 24, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy , Interim Chief Executive Officer and Board Chair of LivaNova , will present in a fireside chat at the Baird Global Healthcare Conference in New York .

LONDON --(BUSINESS WIRE)--Jul. 26, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights 1 Second-quarter revenue of $293.9 million increased

LONDON --(BUSINESS WIRE)--Jun. 14, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m.   London time ( 8 a.m. Eastern Time ).

LONDON --(BUSINESS WIRE)--Jun. 13, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study , “A P r ospective, Multi-c e nter, Randomized C ontrolled

LONDON --(BUSINESS WIRE)--May 3, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights 1 First-quarter revenue of $263.4 million

LONDON --(BUSINESS WIRE)--Apr. 14, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effective immediately, Chair of the Board William A.

LONDON --(BUSINESS WIRE)--Mar. 22, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m.   London time ( 8 a.m. Eastern Time ).

LONDON --(BUSINESS WIRE)--Mar. 9, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM).

LONDON --(BUSINESS WIRE)--Mar. 9, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida .

LONDON --(BUSINESS WIRE)--Feb. 22, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023. Fourth-Quarter Financial Summary and Highlights 1

LONDON --(BUSINESS WIRE)--Feb. 8, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the start of a limited commercial release for the Essenz™ Perfusion System*. The release has been initiated in select centers throughout Europe ,

New device expands access to the latest technology for legacy VNS Therapy patients with drug-resistant epilepsy in the U.S. LONDON --(BUSINESS WIRE)--Feb. 2, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO™, an implantable

LONDON --(BUSINESS WIRE)--Jan. 18, 2023-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results on Wednesday, February 22, 2023 at 1 p.m.   London time ( 8 a.m. Eastern Time ).